State Street Corp Increases Stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

State Street Corp raised its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 30.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 174,529 shares of the company’s stock after buying an additional 40,500 shares during the period. State Street Corp owned approximately 0.27% of SELLAS Life Sciences Group worth $218,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC purchased a new stake in shares of SELLAS Life Sciences Group during the second quarter worth approximately $39,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Up 0.9 %

Shares of NASDAQ:SLS opened at $1.08 on Friday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.72. The stock has a market cap of $76.01 million, a price-to-earnings ratio of -1.57 and a beta of 2.39. The firm’s 50 day moving average price is $1.11 and its 200 day moving average price is $1.18.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.